Rolipram

In the clinical treatment of central nervous system diseases and inflammatory diseases, phosphodiesterase 4 (PDE4) inhibitors have been a hot research and development direction in recent years, and rolipram is a representative selective inhibitor targeting this target. It specifically inhibits the activity of PDE4 to increase the level of cyclic adenosine monophosphate (cAMP) in cells, thereby inhibiting the release of pro-inflammatory factors and regulating neurotransmitter conduction. In the early stage, it was mainly used in clinical research on depression, and subsequent studies have found that it has potential therapeutic value in the fields of inflammatory and neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease, chronic obstructive pulmonary disease and psoriasis. It is a commonly used tool compound in the field of basic research and new drug research and development, and also provides an important molecular reference for the development of innovative drugs for related indications.

Rolipram has not been approved for marketing in the mainstream markets around the world, and is only circulated as a scientific research reagent and an intermediate for drug research and development. There is no public data on the commercial market scale for the time being. From the perspective of the research and development side, more than 2,000 preclinical studies and early clinical trials involving rolipram have been made public worldwide. With the increasing research and development enthusiasm for PDE4 target-related indications, the annual growth rate of demand for related research-grade raw materials has remained at about 12% in the past five years. The supply side is dominated by global professional scientific research reagent manufacturers and custom synthesis enterprises, and no monopoly pattern has been formed. Domestic demand mainly comes from the laboratory research stage of universities, research institutes and new drug research and development enterprises.

Rolipram was originally developed by Schering AG of Germany, and there is no original research trade name approved for marketing worldwide for the time being. The core compound patent expired in the 1990s. At present, there are no approved commercial dosage forms and specifications, and it is not included in the *Catalogue of Chemical Drugs* of China or the Reference Listed Drug Catalogue of the FDA. There is no relevant marketing authorization application number (status A) for rolipram active pharmaceutical ingredient or approved marketed preparation products on the China National Medical Products Administration platform. At the current stage, rolipram raw materials circulated in China are only used for scientific research and shall not be used for clinical purposes. (Data as of October 2024, please refer to the official website of CDE for the latest information)

In response to the needs of impurity research and quality control in the research and development process of rolipram, CATO provides a full set of impurity reference standards for this API. Most products can be supplied directly from stock, and stock orders submitted before 16:00 can be shipped on the same day. All products meet the regulatory requirements of multiple regions such as the Chinese Pharmacopoeia and FDA, and can provide stable compliance support for drug research and development projects at different stages.